Purpose: Previous studies have shown that cannabinoid 2 agonists have anticancer effects on different cancer cell lines. However, the effect of L-759,633 on the C6 and SH-SY5Y cell lines is still unclear. The current study was designed to investigate the potential cytotoxic effects of a cannabinoid 2 agonist L-759,633 on the C6 and SH-SY5Y cell lines. Material and Methods: In this study, the C6 and SH-SY5Y cell lines were used. For each cell line two cell groups were prepared to examine the effect of L-759,633 on C6 glioma and SH-SY5Y cell death. It was not applied any treatment to the cells in the control groups. Various concentrations (5, 10, 20, 40 and 80 μM) of L-759,633 was applied to the cells in the L-759,633 groups. After 24 hours the cell viability was examined using XTT assay. Total oxidant status (TOS) and Total antioxidant status (TAS) in the cells were measured by commercial kits. Results: L-759,633 at the concentrations of 5, 10, 20, 40 and 80 μM significantly decreased the cell viability in C6 cells (p < 0.001). It also significantly increased the TOS levels (p < 0.001) whereas didn’t alter the TAS levels (p > 0.05). On the other hand this agent did not reduce SH-SY5Y cell viability. Conclusion: L-759,633 has antiproliferative effect on C6 cells. Additionally, one of the potential mechanisms involved in this effect is activation the oxidant generation. However this drug didn’t show antiproliferative effect on SH-SY5Y cell. Keywords: L-759,633, Oxidative Stress, cell viability, C6 Glioma, SH-SY5Y cell.
Despite the fact that narcotics and NSAIDs are the mainstays of nociceptive pain care, only a small proportion of neuropathic pain patients benefit from them. Cannabinoid agents could be a viable alternative to opioids in the management of chronic pain. The goal of our investigation was to assess the analgesic efficacy of SER 601 and L-759,633, cannabinoid receptor 2 (CB2) agonists, at various doses in a model of neuropathic pain generated in rat. The analgesic effect of CB2 agonists L-759,633 and SER 601 at various doses in a rat model of neuropathic pain created by partial sciatic nerve ligation was examined by the hot plate method. Furthermore, a comparison of analgesic effects of both drugs with pregabalin is also conducted. The two substances demonstrated a dose-dependent analgesic effect in this model. The analgesic response of SER601 and L-759,633 in the neuropathic pain model was higher compared to that of pregabalin. All in all, our data suggest that SER601 and L-759,633 may offer a beneficial treatment option for neuropathic pain in future.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes owing to their effectiveness in glycemic control
Neuropathic pain, resulting from damage or dysfunction of the nervous system, presents significant clinical challenges due to its chronic nature and resistance to treatment. This study compared the thermal nociception and inflammatory mechanisms of two neuropathic pain models: Sciatic nerve ligation (SNL) and oxaliplatin-induced peripheral neuropathy. Male Wistar Albino rats were randomly assigned to control, SNL, and oxaliplatin-induced neuropathy. The SNL model was established through partial sciatic nerve ligation, while oxaliplatin (4 mg/kg) was administered intraperitoneally twice weekly for four weeks. Thermal nociception was evaluated using tail-flick and hot-plate tests, and inflammatory markers (TNF-α and IL-1β) were measured in dorsal root ganglia(DRG) tissue and serum using ELISA. Thermal analgesia tests revealed that neuropathic pain symptoms appeared from the second week in the oxaliplatin group and from the fourth week in both models (p